Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Nov 30, 2015
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Keytruda Shows Anti-Melanoma Activity in Three Combinations and Phase III Trial

 

Merck presented three studies investigating the use of Keytruda (pembrolizumab), an anti-PD-1 therapy, in combination with three other immunotherapies—epacadostat, Imlygic (talimogene laherparepvec), and ipilimumab—in patients with advanced melanoma.

Keytruda showed robust anti-tumor activity in all three combinations studied. The findings were featured in separate oral presentations at the International Congress of the Society for Melanoma Research, in San Francisco.

Additionally, updated data presented from a phase III study of Keytruda as a single agent showed superior overall response rates and progression free survival compared to ipilimumab in ipilimumab-naïve patients, with twice as many patients achieving PFS on Keytruda compared to ipilimumab.



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter